Literature DB >> 330288

Diclofenac (Voltaren) for the treatment of osteo-arthrosis: a double-blind comparison with naproxen.

P Siraux.   

Abstract

A double-blind, between-patient, comparative trial of diclofenac (Voltaren) and naproxen was carried out in 30 patients suffering from osteo-arthrosis of the hip or the knee. The drugs were given twice daily, morning and evening, during a period of two weeks. The daily dose was 100 mg for Voltaren and 500 mg for naproxen. The results indicate that Voltaren brought relief of pain and stiffness in a greater number of patients than did naproxen. The same finding was made regarding the influence on the range of joint movements, the difference reaching statistical significance. Voltaren appeared also to be better tolerated since the number of patients reporting side-effects was smaller and the complaints of less severity.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 330288     DOI: 10.1177/030006057700500305

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  4 in total

1.  Outcome measurement in osteoarthritis clinical trials: the case for standardisation.

Authors:  N Bellamy; W W Buchanan
Journal:  Clin Rheumatol       Date:  1984-09       Impact factor: 2.980

Review 2.  Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

Review 3.  Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-10       Impact factor: 9.546

Review 4.  Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin.

Authors:  R N Brogden; R C Heel; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-07       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.